Celltrion develops anticancer drugs using ADC platform

Use platform technology for a total of 15 targets

Accelerate Development of ADC Anti-cancer Drugs

Celltrion announced on the 17th that it has signed a contract with domestic bio company Pinotbio to introduce options for implementing ADC Linker-Payload platform technology.

 

With this contract, Celltrion paid advance payments and secured the right to utilize Pinotbio's ADC Linker-PINOT-ADC for up to 15 targets.

 

Celltrion plans to develop ADC anticancer drugs targeting solid cancer by applying PINOT-ADC technology to pipeline candidate materials under development.

 

For a total of 15 target options secured this time, Celltrion can use the technology for one target for each option event, and advance payments, milestones, and royalties for each option event are set separately.

 

ADC Linker-PBD technology is a technology that combines payloads with excellent therapeutic effects with antibodies that react only to specific antigens so that drugs can selectively act on cells expressing antigens.

 

The maximum therapeutic effect can be expected with the minimum drug administration, and the drug can be selectively delivered to the target cell.

 

Celltrion has secured anticancer drugs such as blood cancer treatment Truxima, breast and gastric cancer treatment Herzuma, metastatic direct bowel cancer, non-small cell lung cancer, and ovarian cancer treatment Begzelma.

 

The contract is expected to enable the development of more diverse anticancer drugs by securing options for implementing ADC platform technology.

 

Celltrion signed a contract with Pinotbio to introduce platform technology implementation options, as well as a stake investment and joint research contract.

 

The two companies decided to focus their development capabilities as much as possible to achieve the joint goal of developing ADC treatments while establishing a long-term partnership through equity investment and joint research contracts.

 

An official from Celltrion said, "The introduction of Linker-Payload platform technology has added momentum to the development of ADC anticancer drugs as a future growth engine project.

 

We will actively expand new growth engines through continuous cooperation with promising biotech such as Pinotbio."